News

Boston Scientific has received 510(k) clearance to market its WallFlex Biliary RX fully and partially covered stents, for the palliative treatment of malignant bile duct strictures from the

Orexo said that its partner ProStrakan has reported that the New Drug Application (NDA) filing for Abstral has been accepted for review by the FDA. Abstral is a

BioReliance has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological

Particle Sciences has revealed that Dow Corning has partnered with the company to develop technology for its product development project. The company said that it is leveraging its

Helix BioPharma has provided updates on progress in its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs, following pre-investigational new drug (pre-IND) meetings with the FDA. In

PDS Biotechnology has completed GLP toxicology studies of its HPV-cancer product. The studies, which included pharmacokinetic (PK) and adsorption, bio-distribution and excretion (ADE) studies in addition to the

GlaxoSmithKline (GSK) has entered into a long-term joint venture with Jiangsu Walvax Biotech (Walvax) to develop and manufacture paediatric vaccines for the Chinese market. Reportedly, the joint venture

Acadia Pharmaceuticals has provided an update on its phase III program with pimavanserin for Parkinson’s disease psychosis (PDP). The trial is being conducted in collaboration with Biovail Laboratories,

Ground Zero Pharma (GZP) has opened a new office in downtown Brisbane, Australia in July, to better support an expanding Australian clientele in taking their programs to the